Brand new for the in vitro diagnosis of allergic diseases are related to molecular diagnostics. It implies a new way to diagnose a new nomenclature of allergenic components.
A new guide to facilitate the systematic nomenclature of the components of allergenic sources. The procedure is to use the first three letters of the genre of the allergen source and the first letter of the identifier of the species. Progress and developments in the field of recombinant allergens have allowed the development of a new concept in the diagnosis of allergy. Molecular diagnostics can identify potential molecules responsible for the disease. The use of allergenic components and the proper interpretation of the results of clinical trials require a degree of knowledge on the basis of allergenic components and their clinical implications.
The aim of molecular diagnostics to determine the primary sensitization or specific species and possible cross-reactivity with similar proteins. This molecular diagnosis helps to assess the risk of reaction to exposure to different allergen sources. It is a support tool for choosing the right individual treatment and selecting suitable allergens for specific immunotherapy and to determine the food challenge test.
The most important aspect is the identification of the nature of the protein responsible for raising awareness, in order to assess the risk of serious systemic reactions. The molecular diagnosis is a revolution in the field of diagnosis of allergy with a strong conceptual change, involving a new clinical and analytical study of the allergic patient, which will enhance new therapeutic options approach.
Regarding the treatment of allergic diseases, we have a new drug, widely used in severe allergic diseases, especially in severe bronchial asthma, spontaneous chronic urticaria in, in severe atopic dermatitis and food allergy desensitization accurate.
The most commonly used drug is Omalizumab, which is a humanized anti-IgE monoclonal antibody obtained by recombinant DNA technology, from a mammalian cell line Chinese hamster ovary (CHO). It is indicated in children aged six years and adults. The treatment is performed in hospital units with medical specialists in the treatment of severe allergic diseases.
The drug works by changing the regulation, presentation and release of mediators of allergic reaction. It is envisioned as a treatment in the GINA 2014 guide the strategy for asthma management.
In the future new molecules appear, currently under development, in which we participate in some, like Mepolizumab (IL-5), lebrikizumab (IL-13), Dupilumab (IL-4 and IL-13) and Lilelizumab (anti -IgE).